The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer

•This study is the first to explore the potential cost-effectiveness of targeted SC intervention in currently smoking patients with newly diagnosed non–small cell lung cancer (a high-risk population proven to benefit from quitting smoking).•The LungCast trial (Clinical Trials Identifier NCT01192256) is a real-world data set exploring the prevalence and survival impact of smoking in a cohort of patients with newly diagnosed lung cancer with > 2400 patients tracked for up to 2 years (or until death).•This exploratory analysis can support commissioners in assessing the potential value of investing in dedicated SC services at the point of diagnosis of non–small cell lung cancer.